Astrana Health, Inc. ASTH
At closeNov 6, 2026, 4:53 PM EST
After hours · Nov 6, 4:53 PM ET
- YTD
- +39.06%
- 1 year
- +3.42%
- Market cap
- 1.71B
- Revenue (ttm)
- 3.91B
- Profit margin
- 1.36%
- EPS (ttm)
- 0.83
- Shares out
- 49.60M
- P/E ratio
- 41.57
- Forward P/E
- 9.49
- YTD return
- +39.06%
- 1-year return
- +3.42%
- Volume
- 1.06M
- Avg volume
- 380.01K
- Open
- 36.18
- Previous close
- 39.01
- Day's range
- 31.46 – 36.58
- 52-week range
- 18.08 – 51.60
- Price target
- 51.67 (+49.8%)
- Earnings date
- Nov 5, 2026
5D -1.82 (-5.01%)
Key statistics
- Enterprise value
- 2.28B
- PEG ratio
- 0.00
- Price / sales
- 0.44
- Price / book
- 1.99
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 7.10%
- Free cash flow
- 113.07M
- Total cash
- 396.22M
- Total debt
- 977.38M
- Return on equity
- 9.85%
- Short % of float
- 11.56%
- 50-day average
- 37.06
- 200-day average
- 34.06
Analyst view
- Target (low)
- 41.00
- Target (mean)
- 51.67
- Target (high)
- 65.00
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.65.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.4573 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.3358 | 0.40 | +0.06 | +19.12% |
| May 7, 2026 | Mar 31, 2026 | 0.29 | 0.30 | +0.01 | +3.45% |
| Mar 2, 2026 | Dec 31, 2025 | 0.15 | 0.12 | -0.03 | -20.00% |
| Nov 6, 2025 | Sep 30, 2025 | 0.47 | 0.01 | -0.46 | -97.87% |
| Aug 7, 2025 | Jun 30, 2025 | 0.36 | 0.19 | -0.17 | -47.22% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Needham | main | Buy | Buy |
| Oct 1, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Sep 15, 2026 | Oppenheimer | init | — | Outperform |
| Aug 11, 2026 | Truist Securities | main | Buy | Buy |
| Aug 7, 2026 | Barclays | main | Overweight | Overweight |
| Jul 14, 2026 | TD Cowen | main | Buy | Buy |
About Astrana Health, Inc.
Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United States
- Website
- astranahealth.com
News
Needham Maintains Buy on Astrana Health, Raises Price Target to $45 
Astrana Health Q3 Earnings Call Highlights 
Astrana Health Q3 2026 Earnings Call Transcript 
Astrana Health Narrows FY2026 Sales Guidance from $3.800B-$4.100B to $3.900B-$4.000B vs $3.980B Est 
Astrana Health Q3 EPS $0.26 Misses $0.45 Estimate, Sales $1.023B Beat $1.020B Estimate - Astrana Health Affirms FY2026 Sales Guidance of $3.800B-$4.100B vs $4.004B Est
Oppenheimer Initiates Coverage On Astrana Health with Outperform Rating, Announces Price Target of $53 
Truist Securities Maintains Buy on Astrana Health, Raises Price Target to $55 - Barclays Maintains Overweight on Astrana Health, Raises Price Target to $53
- Astrana Health Affirms FY2026 Sales Guidance of $3.800B-$4.100B vs $4.001B Est
Your note
Sign in to keep a note on ASTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASHO CHANDAN | Chief Operating Officer | Stock Award(Grant) | Mar 4, 2025 | 192,752 |
| CHIANG JOHN | Director | Stock Award(Grant) | Jun 9, 2026 | 35,373 |
| DONG LINDA | Director | Stock Award(Grant) | Jun 9, 2026 | 97,133 |
| KUMAR DINESH M | Officer | Stock Award(Grant) | Mar 31, 2026 | 177,655 |
| LAM THOMAS S | Director | Stock Award(Grant) | Apr 5, 2026 | 7,732,160 |
| MARSH LINDA | Director | Conversion of Exercise of derivative security | Nov 2, 2025 | 92,608 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 19.27% | 6,899,990 | 238.05M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 7.28% | 2,605,775 | 89.90M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 5.44% | 1,946,431 | 67.15M | Jun 29, 2026 |
| State Street Corporation | 4.86% | 1,738,930 | 59.99M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 4.59% | 1,641,428 | 56.63M | Sep 29, 2026 |
| 325 Capital Llc | 4.51% | 1,613,843 | 55.68M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 6.98% | 2,499,020 | 86.22M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.96% | 1,416,817 | 48.88M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 3.29% | 1,177,556 | 40.63M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.85% | 1,021,229 | 35.23M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.65% | 591,784 | 20.42M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.40% | 499,792 | 17.24M | Aug 30, 2026 |